The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 132 participants.
Also called NCT07103655
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 132 participants
- Registry
-
NCT07103655
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07103655. Non-randomized; no masking; primary purpose treatment. Start 2026-03-01 (actual); primary completion 2026-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
- Acronym
- BRAVE-HCM
- Condition
- Hypertrophic Cardiomyopathy (HCM)
- Intervention (Drug)
- mavacamten
- Intervention (Drug)
- Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol
- Intervention (Drug)
- diltiazem
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct07103655- Content hash
5aad7a1548bfb25a1c646bbc468a5484136ace6483f1a3452ffed5fa45b3ae97